Literature DB >> 16795987

Evaluation of CT during arterial portography for preoperative diagnosis of intrahepatic cholangiocarcinoma.

Fumihiko Miura1, Shinichi Okazumi, Wataru Takayama, Takehide Asano, Harufumi Makino, Kiyohiko Shuto, Takenori Ochiai, Tadahiro Takada, Hideki Yasuda, Ikuo Nagashima, Hodaka Amano, Masahiro Yoshida.   

Abstract

BACKGROUND/AIMS: To evaluate computed tomography during arterial portography for preoperative evaluation in patients with intrahepatic cholangiocarcinoma.
METHODOLOGY: Computed tomography during arterial portography was performed in 11 intrahepatic cholangiocarcinoma patients undergoing hepatectomy. Segmental perfusion defect, sensitivity of the main tumor, and sensitivity of intrahepatic metastasis on computed tomography during arterial portography were retrospectively evaluated.
RESULTS: In 9 of 11 patients (81.8%), a segmental perfusion defect was seen. The sensitivities for detecting the main tumor and intrahepatic metastasis were 81.8% and 20%, respectively. In 2 patients, the main tumors existed in segmental perfusion defects and thus were not depicted. In 4 false-negative cases, intrahepatic metastatic lesions existed in the segments that were the counterparts of segmental perfusion defects on computed tomography during arterial portography.
CONCLUSIONS: The sensitivity of computed tomography during arterial portography for diagnosing intrahepatic cholangiocarcinoma and its intrahepatic metastasis was low due to segmental perfusion defect. It is necessary for intrahepatic cholangiocarcinoma to be subjected to systematic segmentectomy including all areas corresponding to the segmental perfusion defect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795987

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  The Application of Three-Dimensional Visualization in Preoperative Evaluation of Portal Vein Invasion in Hilar Cholangiocarcinoma.

Authors:  Jun Zhang; Xiaochao Guo; He Wang; Jixin Zhang; Ping Liu; Qilu Qiao; Xin Wang
Journal:  Cancer Manag Res       Date:  2020-09-29       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.